Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy

Clinical and Experimental Allergy

Volumn 37, Issue 4, 2007, Pages 564-571

  Lund, L ^a   Henmar, H ^a,b   Wurtzen P A ^a   Lund, G ^a   Hjortskov, N ^a   Larsen, J N ^a  

^a ALK ABELLÓ   (Denmark)

^b NONE   (Denmark)

Author keywords

Allergoids; Birch pollen; Histamine release; IgE; Immunotherapy; Intact allergens; T cell proliferation

Indexed keywords

ALLERGOVIT; ALUTARD; DEPIGOID; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POLLEN ANTIGEN; POLLINEX QUATTRO; PURETHRAL; UNCLASSIFIED DRUG; VACCINE;

ALLERGENICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BIRCH; CELL PROLIFERATION; CELL TYPE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ALLERGENS; ANIMALS; BETULA; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; DESENSITIZATION, IMMUNOLOGIC; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN E; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PLANT PROTEINS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; T-LYMPHOCYTES; VACCINES;

EID: 34047192679     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02687.x     Document Type: Article

References (24)

1. Bousquet J, Lockey RF, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53:1-42.
2. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91:709-22.
3. Marsh DG, Lichtenstein LM, Campbell DH. Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970; 18:705-22.
4. Cirkovic TD, Bukilica MN, Gavrovic MD, Vujcic ZM, Petrovic S, Jankov RM. Physicochemical and immunologic characterization of low-molecular-weight allergoids of Dactylis glomerata pollen proteins. Allergy 1999; 54:128-34.
5. Kahlert H, Cromwell O, Fiebig H. Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c. Clin Exp Allergy 2003; 33:1266-72.
6. Casanovas M, Fernandez-Caldas E, Alamar R, Basomba A. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137: 211-8.
7. Ibarrola I, Sanz ML, Gamboa PM et al. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 2004; 34:303-9.
8. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449-59.
9. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60:801-7.
10. Cirkovic T, Gavrovic-Jankulovic M, Prisic S et al. The influence of a residual group in low-molecular-weight allergoids of Artemisia vulgaris pollen on their allergenicity, IgE- and IgGbinding properties. Allergy 2002; 57:1013-20.
11. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen - Eine Analyse der UWA-Meldungen von 1991 bis 2000. Bundesgesunsheitbl-Gesundheitforsch- Gesundheitsschutz 2001; 44:709-18.
12. Kleine-Tebbe J. Schlusswort. Deutsches Arzteblatt 2003; 100:A1688-690.
13. Bousquet J, Hejjaoui A, Skassa-Brociek W et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987; 80:591-8.
14. Schramm G, Kahlert H, Suck R et al. Allergen engineering: variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999; 162:2406-14.
15. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-81.
16. Swoboda I, De WN, Bhalla PL et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002; 32:270-80.
17. Kalinski P, Lebre MC, Kramer D, De Jong EC, Van Schijndel JW, Kapsenberg ML. Analysis of the CD41 T cell responses to house dust mite allergoid. Allergy 2003; 58:648-56.
18. Petersen AB, Gudmann P, Milvang-Gronager P et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004; 37:882-92.
19. Wurtzen PA, Nissen MH, Claesson MH. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol 2001; 53:579-87.
20. Finney DJ. Statistical methods in biological assay, 3rd edn. London: Charles Griffin & Company LTD, 1978, Chapter 4.
21. Dormann D, Ebner C, Jarman ER, Montermann E, Kraft D, Reske-Kunz AB. Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids). Clin Exp Allergy 1998; 28:1374-83.
22. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29:1326-35.
23. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H. T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000; 165:1807-15.
24. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389-97.